share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  07/01 08:03
Moomoo AI 已提取核心訊息
On June 28, 2024, Cingulate Inc., a Delaware-incorporated biopharmaceutical company, announced the entry into a material definitive agreement with certain holders of its existing warrants. The agreement involves the exercise of warrants for approximately 3.19 million shares of common stock at a reduced price of $0.585 per share, with the closing expected on or about July 1, 2024. The company anticipates gross proceeds of roughly $1.86 million, before fees and expenses. The funds are intended for the development and commercialization of CTx-1301, among other corporate purposes. Additionally, Cingulate has engaged H.C. Wainwright & Co. as the exclusive placement agent for the transaction. The company also plans to issue new Series C and D warrants as part of the agreement. The shares underlying the existing warrants are registered with the SEC, and Cingulate has committed to filing a registration statement for the resale of the shares issuable upon exercise of the new warrants. The announcement was made in conjunction with a press release and a Form 8-K filing with the SEC.
On June 28, 2024, Cingulate Inc., a Delaware-incorporated biopharmaceutical company, announced the entry into a material definitive agreement with certain holders of its existing warrants. The agreement involves the exercise of warrants for approximately 3.19 million shares of common stock at a reduced price of $0.585 per share, with the closing expected on or about July 1, 2024. The company anticipates gross proceeds of roughly $1.86 million, before fees and expenses. The funds are intended for the development and commercialization of CTx-1301, among other corporate purposes. Additionally, Cingulate has engaged H.C. Wainwright & Co. as the exclusive placement agent for the transaction. The company also plans to issue new Series C and D warrants as part of the agreement. The shares underlying the existing warrants are registered with the SEC, and Cingulate has committed to filing a registration statement for the resale of the shares issuable upon exercise of the new warrants. The announcement was made in conjunction with a press release and a Form 8-K filing with the SEC.
2024年6月28日，註冊於特拉華州的生物製藥公司Cingulate Inc.宣佈與其現有認股權證某些持有人進入重大實質性協議。該協議涉及以每股0.585美元的優惠價格行使大約319萬股普通股的認股權證，預計於2024年7月1日或前後完成交割。公司預計募集的總資金約爲186萬美元，不包括費用和開支。這些資金將用於開發和商業化CTx-1301，以及其他公司事務。另外，Cingulate還聘請了H.C. Wainwright & Co.作爲這筆交易的獨家配售代理。公司還計劃作爲該協議的一部分發行新的C和D系列認股權證。現有認股權證下的股份已在美國證券交易委員會註冊，Cingulate已承諾提交註冊聲明以便轉售可行行使的新認股權證發行的股份。該公告是與新聞發佈會和提交美國證券交易委員會的8-K表格一起發佈的。
2024年6月28日，註冊於特拉華州的生物製藥公司Cingulate Inc.宣佈與其現有認股權證某些持有人進入重大實質性協議。該協議涉及以每股0.585美元的優惠價格行使大約319萬股普通股的認股權證，預計於2024年7月1日或前後完成交割。公司預計募集的總資金約爲186萬美元，不包括費用和開支。這些資金將用於開發和商業化CTx-1301，以及其他公司事務。另外，Cingulate還聘請了H.C. Wainwright & Co.作爲這筆交易的獨家配售代理。公司還計劃作爲該協議的一部分發行新的C和D系列認股權證。現有認股權證下的股份已在美國證券交易委員會註冊，Cingulate已承諾提交註冊聲明以便轉售可行行使的新認股權證發行的股份。該公告是與新聞發佈會和提交美國證券交易委員會的8-K表格一起發佈的。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息